Send me real-time posts from this site at my email
Motley Fool

Merck's Keytruda Helps Treat an Aggressive Form of Breast Cancer

Chalk up another win for Keytruda, Merck's (NYSE: MRK) cancer drug that seems to be able to be useful in treating almost every type of cancer it's tested against. The most recent results come from a late-stage clinical trial in patients with metastatic triple-negative breast cancer with tumors that express the protein that Keytruda blocks.

Merck said results from the Keynote-355 study showed that Keytruda plus chemotherapy delayed cancer progression and kept patients alive longer than chemotherapy alone. The company did not disclose how much better the combination performed, however; it's saving the details for a presentation at a future medical meeting.

This was only an interim peek at the data, and the clinical trial will continue so it can measure overall survival, which is arguably a more important endpoint for patients and doctors. In the meantime, the pharmaceutical company plans to discuss the results with the FDA and other regulators to potentially get the drug approved to treat this type of cancer.

Image source: Getty Images.

Triple-negative breast cancer gets its name because the cancer cells lack receptors for both estrogen and progesterone, and do not produce excessive amounts of human epidermal growth factor receptor 2 (HER2). A large share of other cancer drugs disrupt the effects of estrogen, progesterone, or HER2 on breast cancer cells, and are therefore ineffective against the triple-negative variety. This limits the treatment options, which means that triple-negative breast cancer tends to be particularly aggressive and has a high recurrence rate.

Keytruda blocks the interaction of a protein on immune cells called programmed cell death 1 (PD-1) with a protein expressed on cancer cells (PD-L1) that tells immune cells not to attack them. By blocking the interaction, Keytruda induces the immune cells to attack the tumor. Since the mechanism is a fairly universal way that tumors avoid being targeted by the immune system, Merck has been able to show that the drug improves outcomes in more than a dozen different types of cancer.

10 stocks we like better than Merck & Co.
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Merck & Co. wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of December 1, 2019

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.


Popular posts

Welcome!!! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue